Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity

Abstract

Over the last decade, due to the high expectations that biologic drugs like anti-TNF are raising, the appropriate identification of patients eligible for these treatments has been conditioned by numerous ordinary aspects, mainly represented by previous or ongoing comorbidities and related therapies, and chronic infections or recurrence of acute infections. Additionally, in the last years, due to close monitoring by experienced clinicians, remarkable changes have been also obtained in the field of safety. Another question mark refers to the management of psoriatic arthritis systemic manifestations, in which the impact of biologic therapy is not enough explored.

Keywords:

• anti-TNF-α
• effectiveness
• psoriatic arthritis
• toxicity

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.